Active, not recruitingPhase 2NCT04388839
Evolutionary Therapy for Rhabdomyosarcoma
Studying Rhabdomyosarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Principal Investigator
- Jonathan Metts, MD, MDMoffitt Cancer Center
- Intervention
- Vincristine(drug)
- Enrollment
- 12 target
- Eligibility
- All sexes
- Timeline
- 2020 – 2027
Study locations (18)
- University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States
- Children's Hospital of Colorado, Aurora, Colorado, United States
- Connecticut Children's Medical Center, Hartford, Connecticut, United States
- University of Florida, Gainesville, Florida, United States
- University of Miami - Sylvester Comprehensive Cancer Center, Miami, Florida, United States
- Johns Hopkins All Children's Hospital, St. Petersburg, Florida, United States
- Moffitt Cancer Center, Tampa, Florida, United States
- Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
- Montefiore Medical Cancer Center, The Bronx, New York, United States
- University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
- Carolinas Medical Center, Levine Cancer Institute, Charlotte, North Carolina, United States
- Duke Children's Hospital, Durham, North Carolina, United States
- Cleveland Clinic, Cleveland, Ohio, United States
- Nationwide Children's Hospital, Columbus, Ohio, United States
- Vanderbilt - Ingram Cancer Center, Nashville, Tennessee, United States
- +3 more locations on ClinicalTrials.gov
Collaborators
National Pediatric Cancer Foundation
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04388839 on ClinicalTrials.govOther trials for Rhabdomyosarcoma
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONNCT07449949A Single-Arm Study on the Efficacy of Sequential Chemoradiotherapy Followed by Surgery in Adult Nasal and Paranasal Sinus RhabdomyosarcomaEye & ENT Hospital of Fudan University
- RECRUITINGPHASE1NCT06865664FGFR4 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory RhabdomyosarcomaNational Cancer Institute (NCI)
- RECRUITINGNCT06924463Identification of Specific Molecular Signatures in Pediatric, Adolescent, and Young Adult Rhabdomyosarcoma Through Spatial Proteome Analysis Using Mass SpectrometryLille University
- RECRUITINGPHASE1, PHASE2NCT06456892Effectiveness of Pucotenlimab Combined With Standard Chemotherapy RegimenSun Yat-sen University
- RECRUITINGPHASE2NCT06023641Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk DiseaseSt. Jude Children's Research Hospital
- RECRUITINGPHASE2NCT05457829Doxorubicin Hydrochloride Liposome Combined With Irinotecan (AI Regimen) Versus VIT Regimen in the Treatment of First Relapsed and Refractory Pediatric Rhabdomyosarcoma: a Prospective, Open-label, Randomized Controlled, Multicenter, Phase II Clinical StudySun Yat-sen University
- RECRUITINGPHASE1, PHASE2NCT04796012VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid TumorsUniversity of Texas Southwestern Medical Center
- RECRUITINGPHASE1NCT04995003HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced SarcomaBaylor College of Medicine